Ohio University and two researcher-inventors have sold partial royalty income rights to its license for the growth hormone antagonist drug Somavert to a private equity firm managed by DRI Capital, reports
MicrOHscope.
The five-year agreement could net OU and its inventors up to $52 million for new biomedical research and technology commercialization initiatives.
Read the full story
here.